NO20011555L - Oral dosage formulations comprising (2S, 3S, 5R) -2- (3,5-difluorophenyl) -3,5-dimethyl-2-morpholinol and an effective stabilizing amount of alginic acid - Google Patents

Oral dosage formulations comprising (2S, 3S, 5R) -2- (3,5-difluorophenyl) -3,5-dimethyl-2-morpholinol and an effective stabilizing amount of alginic acid

Info

Publication number
NO20011555L
NO20011555L NO20011555A NO20011555A NO20011555L NO 20011555 L NO20011555 L NO 20011555L NO 20011555 A NO20011555 A NO 20011555A NO 20011555 A NO20011555 A NO 20011555A NO 20011555 L NO20011555 L NO 20011555L
Authority
NO
Norway
Prior art keywords
morpholinol
difluorophenyl
dimethyl
alginic acid
oral dosage
Prior art date
Application number
NO20011555A
Other languages
Norwegian (no)
Other versions
NO20011555D0 (en
Inventor
Samuel Bruce Balik
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20011555L publication Critical patent/NO20011555L/en
Publication of NO20011555D0 publication Critical patent/NO20011555D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet adskilte orale doseringsformer, typisk tabletter eller kapsler, inneholdende (2S,3S,5R)-2-(3,5-difluorfenyl)-3,5-dimetyl-2-morfolinol eller et fysiologisk akseptabelt salt eller solvat derav, eller et solvat av nevnte salt, og en effektiv stabiliserende mengde alginsyre. Disse doseringsformene er nyttige for forhindring eller behandling av manglende oppmerksomhetshyperkinetikk- forstyrrelse eller depresjon, eller for behandling av avhengighet av nikotin- inneholdende produkter, spesielt tobakkinneholdende produkter, så som behjelpe opphør av røking.Separate oral dosage forms, typically tablets or capsules, containing (2S, 3S, 5R) -2- (3,5-difluorophenyl) -3,5-dimethyl-2-morpholinol or a physiologically acceptable salt or solvate thereof are disclosed, or a solvate of said salt, and an effective stabilizing amount of alginic acid. These dosage forms are useful for preventing or treating lack of attentional hyperkinetic disorder or depression, or for treating addiction to nicotine-containing products, especially tobacco-containing products, such as assisting cessation of smoking.

NO20011555A 1998-09-28 2001-03-27 Oral dosage formulations comprising (2S, 3S, 5R) -2- (3,5-difluorophenyl) -3,5-dimethyl-2-morpholinol and an effective stabilizing amount of alginic acid NO20011555D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10211298P 1998-09-28 1998-09-28
PCT/EP1999/007117 WO2000018406A1 (en) 1998-09-28 1999-09-24 Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid

Publications (2)

Publication Number Publication Date
NO20011555L true NO20011555L (en) 2001-03-27
NO20011555D0 NO20011555D0 (en) 2001-03-27

Family

ID=22288187

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011555A NO20011555D0 (en) 1998-09-28 2001-03-27 Oral dosage formulations comprising (2S, 3S, 5R) -2- (3,5-difluorophenyl) -3,5-dimethyl-2-morpholinol and an effective stabilizing amount of alginic acid

Country Status (17)

Country Link
EP (1) EP1117407A1 (en)
JP (1) JP2002525328A (en)
KR (1) KR20010075385A (en)
CN (1) CN1328459A (en)
AR (1) AR022673A1 (en)
AU (1) AU6087399A (en)
BR (1) BR9914096A (en)
CA (1) CA2345638A1 (en)
CZ (1) CZ20011142A3 (en)
HU (1) HUP0103459A2 (en)
IL (1) IL142054A0 (en)
MA (1) MA26693A1 (en)
NO (1) NO20011555D0 (en)
PE (1) PE20001087A1 (en)
PL (1) PL346877A1 (en)
TR (1) TR200100863T2 (en)
WO (1) WO2000018406A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use

Also Published As

Publication number Publication date
TR200100863T2 (en) 2001-07-23
MA26693A1 (en) 2004-12-20
KR20010075385A (en) 2001-08-09
CN1328459A (en) 2001-12-26
NO20011555D0 (en) 2001-03-27
IL142054A0 (en) 2002-03-10
CZ20011142A3 (en) 2001-09-12
PL346877A1 (en) 2002-03-11
WO2000018406A1 (en) 2000-04-06
JP2002525328A (en) 2002-08-13
AR022673A1 (en) 2002-09-04
BR9914096A (en) 2001-07-31
PE20001087A1 (en) 2000-10-20
HUP0103459A2 (en) 2002-01-28
EP1117407A1 (en) 2001-07-25
AU6087399A (en) 2000-04-17
CA2345638A1 (en) 2000-04-06

Similar Documents

Publication Publication Date Title
BE2011C013I2 (en)
MXPA02006780A (en) Novel substituted benzimidazole dosage forms and method of using same.
EE04962B1 (en) The quinoline compound, the pharmaceutical composition containing it, the use of the compound as a medicament, and the process for the preparation of the compound and the composition
EE04463B1 (en) 3-Arylpropanoic acid derivatives and their analogues, process for their preparation, pharmaceutical compositions containing them and compounds for use in therapy
UA63993C2 (en) Pharmaceutical flash-melt oral dosage forms (variants) and method for their preparation
NO332857B1 (en) Inhalation capsule and use of such
HUP9701694A3 (en) Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds
SE8804629D0 (en) NEW THERAPEUTICALLY ACTIVE COMPOUNDS
WO2000078294A3 (en) Oral administration form for administering a fixed tramadol and diclofenac combination
WO2001080837A3 (en) Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication
DK140393A (en) Iodized uracil nickeloside, this compound for use against an adenovirus infection, use of the compound for the manufacture of a drug for an adenovirus infection, pharmaceutical compositions containing the compound, and method for the preparation of the compound
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
MXPA04003346A (en) Flashmelt oral dosage formulation.
SE8804628D0 (en) NEW COMPOUNDS
YU242789A (en) New compound, 4-fluoro-2-//(4-metoxy-2-pyridin-yl)methylsulphinyl/-1h-benzimidazole and process for obtaining
NO20011555L (en) Oral dosage formulations comprising (2S, 3S, 5R) -2- (3,5-difluorophenyl) -3,5-dimethyl-2-morpholinol and an effective stabilizing amount of alginic acid
FR2500303B1 (en)
AU7775398A (en) Novel glycosylated ginkgolide derivatives, their application as medicines and pharmaceutical compositions
BG105127A (en) Method for treament of nicotine addiction
EE200100196A (en) α-Cyclodextrin Based Pharmaceutical Compositions for Oral Administration of LH-RH Analogs
SE8401968L (en) PROCEDURE FOR PREPARING WELL ABSORBABLE ORAL MEDICINAL DOSAGE FORMS OF MEDICAL 1,4-DIHYDROPYRIDINE DERIVATIVES
GB9211277D0 (en) Pharmaceutical compositions
UY26073A1 (en) ORAL DOSE FORMS
IL122719A0 (en) Controlled release pharmaceutical compositions for oral administration containing nifedipine as active substance
IL134600A0 (en) Intermediates for naphthyl and dihydronaphthyl compounds, pharmaceutical compositions containing them and uses thereof as medicaments in the treatment of post-menopausal syndrome

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application